➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Harvard Business School
Medtronic
Moodys
Dow

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

Litigation Details for GREE, INC v. SUPERCELL OY (E.D. Tex. 2019)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

GREE, INC v. SUPERCELL OY (E.D. Tex. 2019)

Docket   Start Trial Date Filed 2019-02-27
Court District Court, E.D. Texas Date Terminated
Cause 35:271 Patent Infringement Assigned To James Rodney Gilstrap
Jury Demand Plaintiff Referred To
Patents 10,001,469; 10,005,783; 10,028,910; 10,034,873; 10,035,766; 10,040,783; 10,040,859; 10,064,856; 10,064,875; 10,064,901; 10,064,911; 10,073,873; 10,098,910; 10,105,415; 10,105,418; 10,106,546; 10,115,318; 10,117,774; 10,126,299; 10,172,516; 10,172,856; 10,172,861; 10,172,875; 10,342,771; 10,342,859; 10,342,875; 6,019,980; 6,027,469; 6,053,828; 6,080,913; 6,168,016; 6,368,856; 6,469,030; 6,572,873; 6,574,971; 6,616,771; 6,758,771; 6,872,156; 6,875,137; 6,956,027; 6,985,771; 7,056,655; 7,060,875; 7,101,574; 7,137,913; 7,140,988; 7,172,751; 7,342,117; 7,415,858; 7,572,783; 7,604,795; 7,655,038; 7,700,299; 7,700,561; 7,700,775; 7,754,861; 7,775,911; 7,858,070; 7,858,789; 7,872,049; 7,872,050; 7,875,342; 7,910,131; 7,910,758; 7,956,037; 7,956,049; 7,956,067; 7,985,418; 7,985,540; 8,017,980; 8,029,783; 8,038,988; 8,058,418; 8,071,795; 8,158,616; 8,288,116; 8,288,165; 8,288,320; 8,299,106; 8,318,750; 8,318,758; 8,388,971; 8,388,985; 8,415,342; 8,481,055; 8,481,064; 8,481,067; 8,540,967; 8,561,859; 8,574,102; 8,574,856; 8,574,858; 8,604,014; 8,604,057; 8,754,011; 8,754,045; 8,754,065; 8,754,070; 8,754,078; 8,754,090; 8,754,096; 8,754,106; 8,754,108; 8,754,109; 8,754,131; 8,771,758; 8,771,956; 8,795,107; 8,795,108; 8,795,725; 8,828,956; 8,859,023; 8,859,509; 8,859,572; 8,859,795; 8,901,299; 8,956,288; 8,980,901; 9,023,783; 9,033,828; 9,066,856; 9,066,980; 9,073,858; 9,073,988; 9,096,861; 9,101,540; 9,101,669; 9,107,898; 9,156,859; 9,320,750; 9,358,215; 9,415,098; 9,415,102; 9,561,066; 9,561,068; 9,561,080; 9,561,175; 9,561,288; 9,561,331; 9,572,856; 9,572,861; 9,604,113; 9,604,901; 9,616,049; 9,616,059; 9,616,061; 9,616,066; 9,616,096; 9,616,105; 9,616,126; 9,616,137; 9,655,956; 9,655,979; 9,669,096; 9,669,106; 9,669,107; 9,669,108; 9,700,561; 9,700,775; 9,751,859; 9,757,418; 9,758,561; 9,758,789; 9,771,358; 9,771,418; 9,775,913; 9,789,057; 9,789,062; 9,789,064; 9,789,078; 9,789,108; 9,789,156; 9,789,165; 9,795,604; 9,828,415; 9,856,320; 9,861,757; 9,861,771; 9,872,862; 9,901,113; 9,910,046; 9,913,901; 9,913,910; 9,956,172; 9,980,910
Link to Docket External link to docket
Biologic Drugs cited in GREE, INC v. SUPERCELL OY

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for GREE, INC v. SUPERCELL OY (E.D. Tex. 2019)

Date Filed Document No. Description Snippet Link To Document
2020-05-11 175 Memorandum & Opinion position: ’655 Patent, at [57] Abstract, col.2 ll.27–32, col.4 ll.24–27, col.9 l.64 – col.10 l.5, col.13 …481 Patent”). In the ’172 Case, Plaintiff asserts U.S. Patent No. 10,286,302 (the “’302 Patent”). … field • ’481 Patent Claim 4 • ’137 Patent Claims 8, 10, 13 Having reviewed…infringement of five U.S. Patents. In the ’070 Case, Plaintiff asserts four U.S. Patents: No. 9,604,137…position: ’873 Patent col.1 ll.24–32, col.4 ll.19–24, col.4 ll.29–32, col.5 ll.29–41, col.5 ll.47– 51 External link to document
2020-05-20 181 ~Util - Terminate Motions AND Memorandum & Opinion knowledge. Brazos River Auth. v. GE Ionics, Inc., 469 F.3d 416, 433 (5th Cir. 2006) (“Thus, a rule 30(b…and Supercell based in Finland. Contending its patents were being infringed, GREE filed several suits… products that allegedly practice the asserted patents. Id. at 4–5; see also Dkt. No. 156 at 4. Second…February 2019 2:19-cv-00070-JRG-RSP Patent Plaintiff District Court, E.D. Texas…portions of GREE’s source code. Dkt. No. 152 at 8–10. In its Motion to Compel, Supercell largely External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Medtronic
Colorcon
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.